A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development.

human factors human-centered design mobile phone participatory medicine personal health record visualization in eHealth

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
06 07 2020
Historique:
received: 25 07 2019
accepted: 04 02 2020
revised: 16 12 2019
entrez: 7 7 2020
pubmed: 7 7 2020
medline: 15 12 2020
Statut: epublish

Résumé

Patients with multiple sclerosis (MS) face several challenges in accessing clinical tools to help them monitor, understand, and make meaningful decisions about their disease course. The University of California San Francisco MS BioScreen is a web-based precision medicine tool initially designed to be clinician facing. We aimed to design a second, openly available tool, Open MS BioScreen, that would be accessible, understandable, and actionable by people with MS. This study aimed to describe the human-centered design and development approach (inspiration, ideation, and implementation) for creating the Open MS BioScreen platform. We planned an iterative and cyclical development process that included stakeholder engagement and iterative feedback from users. Stakeholders included patients with MS along with their caregivers and family members, MS experts, generalist clinicians, industry representatives, and advocacy experts. Users consisted of anyone who wants to track MS measurements over time and access openly available tools for people with MS. Phase I (inspiration) consisted of empathizing with users and defining the problem. We sought to understand the main challenges faced by patients and clinicians and what they would want to see in a web-based app. In phase II (ideation), our multidisciplinary team discussed approaches to capture, display, and make sense of user data. Then, we prototyped a series of mock-ups to solicit feedback from clinicians and people with MS. In phase III (implementation), we incorporated all concepts to test and iterate a minimally viable product. We then gathered feedback through an agile development process. The design and development were cyclical-many times throughout the process, we went back to the drawing board. This human-centered approach generated an openly available, web-based app through which patients with MS, their clinicians, and their caregivers can access the site and create an account. Users can enter information about their MS (basic level as well as more advanced concepts), visualize their data longitudinally, access a series of algorithms designed to empower them to make decisions about their treatments, and enter data from wearable devices to encourage realistic goal setting about their ambulatory activity. Agile development will allow us to continue to incorporate precision medicine tools, as these are validated in the clinical research arena. After engaging intended users into the iterative human-centered design of the Open MS BioScreen, we will now monitor the adaptation and dissemination of the tool as we expand its functionality and reach. The insights generated from this approach can be applied to the development of a number of self-tracking, self-management, and user engagement tools for patients with chronic conditions.

Sections du résumé

BACKGROUND
Patients with multiple sclerosis (MS) face several challenges in accessing clinical tools to help them monitor, understand, and make meaningful decisions about their disease course. The University of California San Francisco MS BioScreen is a web-based precision medicine tool initially designed to be clinician facing. We aimed to design a second, openly available tool, Open MS BioScreen, that would be accessible, understandable, and actionable by people with MS.
OBJECTIVE
This study aimed to describe the human-centered design and development approach (inspiration, ideation, and implementation) for creating the Open MS BioScreen platform.
METHODS
We planned an iterative and cyclical development process that included stakeholder engagement and iterative feedback from users. Stakeholders included patients with MS along with their caregivers and family members, MS experts, generalist clinicians, industry representatives, and advocacy experts. Users consisted of anyone who wants to track MS measurements over time and access openly available tools for people with MS. Phase I (inspiration) consisted of empathizing with users and defining the problem. We sought to understand the main challenges faced by patients and clinicians and what they would want to see in a web-based app. In phase II (ideation), our multidisciplinary team discussed approaches to capture, display, and make sense of user data. Then, we prototyped a series of mock-ups to solicit feedback from clinicians and people with MS. In phase III (implementation), we incorporated all concepts to test and iterate a minimally viable product. We then gathered feedback through an agile development process. The design and development were cyclical-many times throughout the process, we went back to the drawing board.
RESULTS
This human-centered approach generated an openly available, web-based app through which patients with MS, their clinicians, and their caregivers can access the site and create an account. Users can enter information about their MS (basic level as well as more advanced concepts), visualize their data longitudinally, access a series of algorithms designed to empower them to make decisions about their treatments, and enter data from wearable devices to encourage realistic goal setting about their ambulatory activity. Agile development will allow us to continue to incorporate precision medicine tools, as these are validated in the clinical research arena.
CONCLUSIONS
After engaging intended users into the iterative human-centered design of the Open MS BioScreen, we will now monitor the adaptation and dissemination of the tool as we expand its functionality and reach. The insights generated from this approach can be applied to the development of a number of self-tracking, self-management, and user engagement tools for patients with chronic conditions.

Identifiants

pubmed: 32628124
pii: v22i7e15605
doi: 10.2196/15605
pmc: PMC7381029
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15605

Subventions

Organisme : NINDS NIH HHS
ID : R35 NS111644
Pays : United States

Informations de copyright

©Erica Schleimer, Jennifer Pearce, Andrew Barnecut, William Rowles, Antoine Lizee, Arno Klein, Valerie J Block, Adam Santaniello, Adam Renschen, Refujia Gomez, Anisha Keshavan, Jeffrey M Gelfand, Roland G Henry, Stephen L Hauser, Riley Bove. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 06.07.2020.

Références

Mult Scler. 1998 Oct;4(5):444-51
pubmed: 9839306
Ann Neurol. 2014 Nov;76(5):633-42
pubmed: 25263997
JMIR Mhealth Uhealth. 2018 May 24;6(5):e10181
pubmed: 29798832
BMC Med Inform Decis Mak. 2017 Feb 20;17(1):19
pubmed: 28219430
Lancet Neurol. 2007 Dec;6(12):1094-105
pubmed: 18031706
JMIR Form Res. 2019 May 22;3(2):e10951
pubmed: 31120021
Acta Neurol Scand. 2015;132(199):11-9
pubmed: 26046553
J Med Internet Res. 2010 Jun 14;12(2):e19
pubmed: 20542858
Cochrane Database Syst Rev. 2014 Jun 25;(6):CD007131
pubmed: 24963623
JMIR Mhealth Uhealth. 2018 Feb 09;6(2):e37
pubmed: 29426814
JMIR Res Protoc. 2014 Sep 15;3(3):e46
pubmed: 25263541
J Nurs Care Qual. 2016 Apr-Jun;31(2):105-12; quiz 113-4
pubmed: 26447343
Ann Neurol. 2016 Oct;80(4):499-510
pubmed: 27464262
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
JMIR Mhealth Uhealth. 2018 May 23;6(5):e10512
pubmed: 29792295
JMIR Mhealth Uhealth. 2018 Mar 02;6(3):e51
pubmed: 29500159
J Biomed Inform. 2016 Feb;59:15-30
pubmed: 26528606
Prev Chronic Dis. 2018 Sep 27;15:E117
pubmed: 30264690
Am J Prev Med. 2015 Apr;48(4):472-9
pubmed: 25700655
BMC Med Inform Decis Mak. 2014 Dec 14;14:117
pubmed: 25495847
Lancet Neurol. 2018 May;17(5):467-480
pubmed: 29656742
JAMA Netw Open. 2019 Mar 1;2(3):e190570
pubmed: 30874777
Health Informatics J. 2014 Mar;20(1):50-8
pubmed: 24550564

Auteurs

Erica Schleimer (E)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Jennifer Pearce (J)

Plain Language Health, San Francisco, CA, United States.

Andrew Barnecut (A)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

William Rowles (W)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Antoine Lizee (A)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Arno Klein (A)

Child Mind Institute, New York, NY, United States.

Valerie J Block (VJ)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Adam Santaniello (A)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Adam Renschen (A)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Refujia Gomez (R)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Anisha Keshavan (A)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Jeffrey M Gelfand (JM)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Roland G Henry (RG)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Stephen L Hauser (SL)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Riley Bove (R)

Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH